Find a therapist to help with ADHD

Centanafadine is widely called a non-stimulant, but its FDA label classifies it as a stimulant.

Across its trials, the effect size lands at roughly half of amphetamine's, at or below atomoxetine's.

No head-to-head trial against any existing ADHD medication has ever been conducted.

These four reading habits apply to every new psychiatric drug launch, and they are learnable.

In July 2026, the FDA approved centanafadine, sold as Simtriyo, for ADHD. The trade coverage converged on two claims: that it's a first-in-class "triple reuptake inhibitor," and that it offers stimulant-like benefit with better tolerability. I treat ADHD and study its medications, I read all seven trial publications, and both claims survive only with significant fine print. That fine print is a useful case study in how to read any new drug launch, so let's walk through it together.

Our traditional names for psychiatric medication classes create unnecessary confusion. We prescribe "antidepressants" for anxiety disorders and "antipsychotics" for depression, and patients understandably wonder whether their doctor read the chart. Centanafadine extends the tradition: Nearly every article calls it a non-stimulant, while the FDA label classifies it as a central nervous system stimulant, and it's regulated as a scheduled controlled substance.

The chemistry underneath the label matters more than either word. "Triple reuptake inhibitor" suggests balanced action on norepinephrine, dopamine, and serotonin. The published binding data say otherwise: Centanafadine is roughly sixfold less potent at the dopamine transporter and 14-fold less potent at the serotonin transporter than at the norepinephrine transporter. At clinical doses, this is predominantly a norepinephrine drug, pharmacologically closer to the atomoxetine family than to Adderall. That single fact predicts most of what the trials found.

What the Trials Actually Showed

Effect size is the standard way trials express how far treated patients pull ahead of placebo, and it's the fairest yardstick we have for comparing medications that were never tested against each other. Across the four........

© Psychology Today